Compare LUNR & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNR | NBTX |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | France |
| Employees | 525 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | 2018 |
| Metric | LUNR | NBTX |
|---|---|---|
| Price | $12.34 | $38.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | $22.35 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 7.9M | 112.4K |
| Earning Date | 05-11-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $343.00 | $58.17 |
| Revenue Next Year | $16.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.78 | $6.09 |
| 52 Week High | $46.75 | $57.14 |
| Indicator | LUNR | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 50.06 |
| Support Level | $10.49 | $30.15 |
| Resistance Level | $22.25 | $42.40 |
| Average True Range (ATR) | 0.95 | 2.32 |
| MACD | 0.23 | -0.05 |
| Stochastic Oscillator | 19.30 | 50.34 |
Intuitive Machines Inc is a space infrastructure and services company focused on enabling sustained human activity beyond Earth. It designs, builds, integrates, and operates space systems, offering infrastructure-as-a-service across low Earth orbit, geostationary orbit, cislunar space, and deep space. Its capabilities include spacecraft development and space-based network connectivity, serving commercial, civil, and national security customers. The company conducts sales both directly and through an extensive customer and partner network spanning North America, South America, Europe, Asia, and Australia, including rideshare delivery providers, lunar surface mobility providers, payload providers, communication satellite providers, and ground segment providers.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.